<s id="wsj_0975.1"> 23
3 	 0 	 NP[nb]/N 	 1 	 policy A
3 	 1 	 N/N 	 1 	 policy proposed
3 	 2 	 N/N 	 1 	 policy conflict-of-interest
3 	 4 	 (NP\NP)/NP 	 1 	 policy for
3 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 policy may
3 	 10 	 (S[b]\NP)/NP 	 1 	 policy thwart <XB>
6 	 5 	 (N/N)/(N/N) 	 2 	 funded federally
8 	 4 	 (NP\NP)/NP 	 2 	 researchers for
8 	 6 	 N/N 	 1 	 researchers funded
8 	 7 	 N/N 	 1 	 researchers biomedical
9 	 16 	 (S[dcl]\S[dcl])/NP 	 1 	 may say
10 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 thwart may
14 	 10 	 (S[b]\NP)/NP 	 2 	 ventures thwart
14 	 11 	 N/N 	 1 	 ventures many
14 	 12 	 N/N 	 1 	 ventures high-technology
14 	 13 	 N/N 	 1 	 ventures new
17 	 16 	 (S[dcl]\S[dcl])/NP 	 2 	 financiers say
19 	 16 	 (S[dcl]\S[dcl])/NP 	 2 	 researchers say
22 	 16 	 (S[dcl]\S[dcl])/NP 	 2 	 administrators say
22 	 21 	 N/N 	 1 	 administrators university
<\s>
<s id="wsj_0975.2"> 22
2 	 1 	 (N/N)/(N/N) 	 2 	 Institutes National
2 	 3 	 ((N/N)\(N/N))/NP 	 2 	 Institutes of
4 	 3 	 ((N/N)\(N/N))/NP 	 3 	 Health of
5 	 0 	 NP[nb]/N 	 1 	 policy The
5 	 2 	 N/N 	 1 	 policy Institutes
5 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 policy would
5 	 7 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 policy require <XB>
7 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 require would
8 	 7 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 researchers require
8 	 10 	 (S[b]\NP)/NP 	 1 	 researchers cut <XB>
8 	 18 	 (S[b]\NP)/NP 	 1 	 researchers lose <XU>
9 	 7 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to require
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 cut to
12 	 10 	 (S[b]\NP)/NP 	 2 	 ties cut
12 	 11 	 N/N 	 1 	 ties financial
12 	 13 	 (NP\NP)/NP 	 1 	 ties with
15 	 13 	 (NP\NP)/NP 	 2 	 businesses with
15 	 14 	 N/N 	 1 	 businesses health-care
18 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 lose to
21 	 18 	 (S[b]\NP)/NP 	 2 	 money lose
21 	 19 	 NP[nb]/N 	 1 	 money their
21 	 20 	 N/N 	 1 	 money government
<\s>
<s id="wsj_0975.3"> 23
2 	 0 	 (S/S)/NP 	 2 	 concerns Among
2 	 1 	 N/N 	 1 	 concerns other
5 	 4 	 NP[nb]/N 	 1 	 agency the
5 	 6 	 (S[dcl]\NP)/S[dcl] 	 1 	 agency says
6 	 0 	 (S/S)/NP 	 1 	 says Among
7 	 8 	 (NP\NP)/NP 	 1 	 researchers with
7 	 11 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 researchers are
7 	 13 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 researchers likely <XB>
10 	 8 	 (NP\NP)/NP 	 2 	 ties with
10 	 9 	 N/N 	 1 	 ties business
11 	 6 	 (S[dcl]\NP)/S[dcl] 	 2 	 are says
13 	 11 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 likely are
13 	 12 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 likely more
14 	 13 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to likely
15 	 14 	 (S[to]\NP)/(S[b]\NP) 	 2 	 falsify to
15 	 17 	 (((S\NP)\(S\NP))/(S[to]\NP))/N 	 2 	 falsify in
16 	 15 	 (S[b]\NP)/NP 	 2 	 findings falsify
18 	 17 	 (((S\NP)\(S\NP))/(S[to]\NP))/N 	 4 	 order in
19 	 17 	 (((S\NP)\(S\NP))/(S[to]\NP))/N 	 3 	 to in
20 	 19 	 (S[to]\NP)/(S[b]\NP) 	 2 	 tout to
22 	 20 	 (S[b]\NP)/NP 	 2 	 drugs tout
22 	 21 	 N/N 	 1 	 drugs new
<\s>
<s id="wsj_0975.4"> 19
1 	 2 	 (NP\NP)/NP 	 1 	 ties between
1 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 ties have
1 	 8 	 S[pt]\NP 	 1 	 ties blossomed <XB>
3 	 2 	 (NP\NP)/NP 	 2 	 academia between
6 	 2 	 (NP\NP)/NP 	 2 	 capital between
6 	 5 	 N/N 	 1 	 capital venture
7 	 0 	 (S/S)/S[dcl] 	 2 	 have As
8 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 blossomed have
8 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 blossomed in
11 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 years in
11 	 10 	 N/N 	 1 	 years recent
14 	 13 	 N/N 	 1 	 fear governmental
14 	 15 	 (NP\NP)/NP 	 1 	 fear of
14 	 17 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 fear has
14 	 18 	 S[pt]\NP 	 1 	 fear risen <XB>
16 	 15 	 (NP\NP)/NP 	 2 	 abuse of
17 	 0 	 (S/S)/S[dcl] 	 1 	 has As
18 	 17 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 risen has
<\s>
<s id="wsj_0975.5"> 27
2 	 1 	 NP[nb]/N 	 1 	 guidelines the
2 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines could
2 	 4 	 (((S[b]\NP)/(S[to]\NP))/(S[adj]\NP))/NP[expl] 	 1 	 guidelines make <XB>
3 	 0 	 S/S 	 1 	 could But
3 	 11 	 (S[dcl]\S[dcl])/NP 	 1 	 could says
4 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 make could
5 	 4 	 (((S[b]\NP)/(S[to]\NP))/(S[adj]\NP))/NP[expl] 	 4 	 it make
6 	 4 	 (((S[b]\NP)/(S[to]\NP))/(S[adj]\NP))/NP[expl] 	 3 	 impossible make
7 	 4 	 (((S[b]\NP)/(S[to]\NP))/(S[adj]\NP))/NP[expl] 	 2 	 to make
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 commercialize to
9 	 8 	 (S[b]\NP)/NP 	 2 	 research commercialize
13 	 11 	 (S[dcl]\S[dcl])/NP 	 2 	 Smith says
13 	 12 	 N/N 	 1 	 Smith Kenneth
16 	 11 	 (S[dcl]\S[dcl])/NP 	 2 	 provost says
16 	 15 	 N/N 	 1 	 provost associate
19 	 11 	 (S[dcl]\S[dcl])/NP 	 2 	 president says
19 	 18 	 N/N 	 1 	 president vice
19 	 20 	 (NP\NP)/NP 	 1 	 president for
19 	 22 	 (NP\NP)/NP 	 1 	 president at
21 	 20 	 (NP\NP)/NP 	 2 	 research for
24 	 22 	 (NP\NP)/NP 	 2 	 Institute at
24 	 23 	 N/N 	 1 	 Institute Massachusetts
24 	 25 	 (NP\NP)/NP 	 1 	 Institute of
26 	 25 	 (NP\NP)/NP 	 2 	 Technology of
<\s>
<s id="wsj_0975.6"> 17
1 	 0 	 NP[nb]/N 	 1 	 NIH The
1 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 NIH is
1 	 3 	 ((S[ng]\NP)/PP)/NP 	 1 	 NIH asking <XB>
3 	 2 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 asking is
3 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 asking until
5 	 3 	 ((S[ng]\NP)/PP)/NP 	 3 	 recipients asking
5 	 4 	 N/N 	 1 	 recipients grant
7 	 3 	 ((S[ng]\NP)/PP)/NP 	 3 	 others asking
8 	 3 	 ((S[ng]\NP)/PP)/NP 	 2 	 for asking
9 	 8 	 PP/NP 	 1 	 comments for
9 	 10 	 (NP\NP)/NP 	 1 	 comments on
13 	 10 	 (NP\NP)/NP 	 2 	 guidelines on
13 	 11 	 NP[nb]/N 	 1 	 guidelines the
13 	 12 	 N/N 	 1 	 guidelines proposed
15 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 Dec. until
16 	 15 	 N/N[num] 	 1 	 15 Dec.
<\s>
<s id="wsj_0975.7"> 12
1 	 0 	 (S/S)/NP 	 2 	 that After
3 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 it will
3 	 5 	 (S[b]\NP)/NP 	 1 	 it make <XB>
4 	 0 	 (S/S)/NP 	 1 	 will After
5 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 make will
8 	 5 	 (S[b]\NP)/NP 	 2 	 decision make
8 	 6 	 NP[nb]/N 	 1 	 decision a
8 	 7 	 N/N 	 1 	 decision final
8 	 9 	 (NP\NP)/NP 	 1 	 decision on
11 	 9 	 (NP\NP)/NP 	 2 	 policy on
11 	 10 	 NP[nb]/N 	 1 	 policy the
<\s>
<s id="wsj_0975.8"> 35
1 	 0 	 NP[nb]/N 	 1 	 guidelines The
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines could
1 	 3 	 (S[b]\NP)/NP 	 1 	 guidelines foil <XB>
2 	 21 	 (S[dcl]\S[dcl])/NP 	 1 	 could says
3 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 foil could
5 	 3 	 (S[b]\NP)/NP 	 2 	 arrangements foil
5 	 4 	 N/N 	 1 	 arrangements future
5 	 6 	 S[adj]\NP 	 1 	 arrangements similar <XB>
6 	 7 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 similar to
9 	 7 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 deal to
9 	 8 	 NP[nb]/N 	 1 	 deal the
9 	 10 	 (NP\NP)/NP 	 1 	 deal behind
12 	 10 	 (NP\NP)/NP 	 2 	 Inc. behind
12 	 11 	 N/N 	 1 	 Inc. Lithox
17 	 15 	 (N/N)/(N/N) 	 2 	 Mass. Salem
19 	 10 	 (NP\NP)/NP 	 2 	 start-up behind
19 	 14 	 NP[nb]/N 	 1 	 start-up a
19 	 17 	 N/N 	 1 	 start-up Mass.
23 	 21 	 (S[dcl]\S[dcl])/NP 	 2 	 Daly says
23 	 22 	 N/N 	 1 	 Daly Robert
27 	 21 	 (S[dcl]\S[dcl])/NP 	 2 	 partner says
27 	 25 	 NP[nb]/N 	 1 	 partner a
27 	 26 	 N/N 	 1 	 partner managing
27 	 28 	 (NP\NP)/NP 	 1 	 partner of
30 	 28 	 (NP\NP)/NP 	 2 	 Associates of
30 	 29 	 N/N 	 1 	 Associates TA
34 	 28 	 (NP\NP)/NP 	 2 	 firm of
34 	 32 	 NP[nb]/N 	 1 	 firm a
34 	 33 	 N/N 	 1 	 firm venture-capital
<\s>
<s id="wsj_0975.9"> 30
1 	 0 	 (S/S)/NP 	 2 	 $ With
3 	 1 	 N/N[num] 	 1 	 million $
3 	 2 	 N/N 	 1 	 million 2.3
5 	 9 	 (S[dcl]\NP)/NP 	 1 	 he launched
5 	 14 	 (S[b]\NP)/NP 	 1 	 he market <XB>
8 	 7 	 N/N 	 1 	 investors other
8 	 9 	 (S[dcl]\NP)/NP 	 1 	 investors launched
8 	 14 	 (S[b]\NP)/NP 	 1 	 investors market <XB>
9 	 0 	 (S/S)/NP 	 1 	 launched With
9 	 12 	 (S\NP)\(S\NP) 	 2 	 launched year
10 	 9 	 (S[dcl]\NP)/NP 	 2 	 Lithox launched
12 	 11 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 year last
14 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 market to
17 	 14 	 (S[b]\NP)/NP 	 2 	 cure market
17 	 15 	 NP[nb]/N 	 1 	 cure a
17 	 16 	 N/N 	 1 	 cure gallstone
17 	 18 	 (S[ng]\NP)/(S[pss]\NP) 	 1 	 cure being <XB>
17 	 19 	 S[pss]\NP 	 1 	 cure developed <XB>
19 	 18 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 developed being
19 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 developed by
21 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 researchers by
21 	 22 	 (NP\NP)/NP 	 1 	 researchers of
24 	 22 	 (NP\NP)/NP 	 2 	 University of
24 	 23 	 NP[nb]/N 	 1 	 University the
24 	 25 	 (NP\NP)/NP 	 1 	 University of
24 	 27 	 (NP\NP)/NP 	 1 	 University at
26 	 25 	 (NP\NP)/NP 	 2 	 California of
29 	 27 	 (NP\NP)/NP 	 2 	 Diego at
29 	 28 	 N/N 	 1 	 Diego San
<\s>
<s id="wsj_0975.10"> 29
1 	 0 	 NP[nb]/N 	 1 	 researchers The
1 	 3 	 (NP\NP)/(S[dcl]\NP) 	 1 	 researchers who
1 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 researchers are <XB>
1 	 5 	 (S[ng]\NP)/(S[pss]\NP) 	 1 	 researchers being <XB>
1 	 6 	 S[pss]\NP 	 1 	 researchers financed <XB>
1 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 researchers will
1 	 13 	 (S[b]\NP)/NP 	 1 	 researchers receive <XB>
4 	 3 	 (NP\NP)/(S[dcl]\NP) 	 2 	 are who
5 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 being are
6 	 5 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 financed being
6 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 financed by
10 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 funds by
10 	 8 	 NP[nb]/N 	 1 	 funds the
10 	 9 	 N/N 	 1 	 funds Lithox
13 	 12 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 receive will
13 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 receive if
15 	 13 	 (S[b]\NP)/NP 	 2 	 royalty receive
15 	 14 	 NP[nb]/N 	 1 	 royalty a
18 	 13 	 (S[b]\NP)/NP 	 2 	 percentage receive
18 	 14 	 NP[nb]/N 	 1 	 percentage a
18 	 19 	 (N\N)/NP 	 1 	 percentage of
20 	 19 	 (N\N)/NP 	 2 	 sales of
24 	 23 	 NP[nb]/N 	 1 	 research their
24 	 25 	 (S[dcl]\NP)/NP 	 1 	 research yields
25 	 22 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 yields if
28 	 25 	 (S[dcl]\NP)/NP 	 2 	 product yields
28 	 26 	 NP[nb]/N 	 1 	 product a
28 	 27 	 N/N 	 1 	 product commercial
<\s>
<s id="wsj_0975.11"> 33
3 	 2 	 NP[nb]/N 	 1 	 University the
3 	 4 	 (NP\NP)/NP 	 1 	 University of
3 	 12 	 (S[dcl]\NP)/NP 	 1 	 University shares
5 	 4 	 (NP\NP)/NP 	 2 	 California of
10 	 7 	 ((S\NP)/(S\NP))/NP 	 3 	 universities like
10 	 8 	 N/N 	 1 	 universities many
10 	 9 	 N/N 	 1 	 universities other
12 	 1 	 (S/S)/S[dcl] 	 2 	 shares because
12 	 7 	 ((S\NP)/(S\NP))/NP 	 2 	 shares like
12 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 shares with
14 	 12 	 (S[dcl]\NP)/NP 	 2 	 royalties shares
14 	 13 	 NP[nb]/N 	 1 	 royalties its
16 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 researchers with
18 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 it may
18 	 20 	 ((S[b]\NP)/PP)/NP 	 1 	 it disqualify <XB>
19 	 0 	 S/S 	 1 	 may But
19 	 1 	 (S/S)/S[dcl] 	 1 	 may because
19 	 32 	 (S[dcl]\S[dcl])\NP 	 1 	 may says
20 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 disqualify may
20 	 25 	 ((S\NP)\(S\NP))/NP 	 2 	 disqualify under
21 	 20 	 ((S[b]\NP)/PP)/NP 	 3 	 itself disqualify
22 	 20 	 ((S[b]\NP)/PP)/NP 	 2 	 from disqualify
24 	 22 	 PP/NP 	 1 	 funds from
24 	 23 	 N/N 	 1 	 funds federal
28 	 25 	 ((S\NP)\(S\NP))/NP 	 3 	 guidelines under
28 	 26 	 NP[nb]/N 	 1 	 guidelines the
28 	 27 	 N/N 	 1 	 guidelines proposed
31 	 30 	 N/N 	 1 	 Daly Mr.
31 	 32 	 (S[dcl]\S[dcl])\NP 	 2 	 Daly says
<\s>
<s id="wsj_0975.12"> 16
2 	 0 	 NP[nb]/N 	 1 	 industry The
2 	 1 	 N/N 	 1 	 industry high-tech
2 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 industry is
2 	 4 	 (S[adj]\NP)/PP 	 1 	 industry full <XB>
4 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 full is
5 	 4 	 (S[adj]\NP)/PP 	 2 	 of full
7 	 5 	 PP/NP 	 1 	 kind of
7 	 6 	 NP[nb]/N 	 1 	 kind the
7 	 8 	 (NP\NP)/NP 	 1 	 kind of
7 	 10 	 (NP\NP)/(S[dcl]/NP) 	 1 	 kind that
7 	 15 	 (S[b]\NP)/NP 	 2 	 kind affect <XU>
9 	 8 	 (NP\NP)/NP 	 2 	 arrangement of
13 	 11 	 NP[nb]/N 	 1 	 guidelines the
13 	 12 	 N/N 	 1 	 guidelines new
13 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines would
13 	 15 	 (S[b]\NP)/NP 	 1 	 guidelines affect <XB>
14 	 10 	 (NP\NP)/(S[dcl]/NP) 	 2 	 would that
15 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 affect would
<\s>
<s id="wsj_0975.13"> 31
1 	 0 	 (S/S)/NP 	 2 	 instance For
5 	 3 	 N/N 	 1 	 Inc. Commonwealth
5 	 4 	 N/N 	 1 	 Inc. BioVentures
5 	 13 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 Inc. invested
9 	 7 	 NP[nb]/N 	 1 	 concern a
9 	 8 	 N/N 	 1 	 concern venture-capital
9 	 13 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 concern invested
12 	 11 	 ((S\NP)/(S\NP))/((S\NP)/(S\NP)) 	 3 	 month last
13 	 0 	 (S/S)/NP 	 1 	 invested For
13 	 12 	 (S\NP)/(S\NP) 	 2 	 invested month
14 	 13 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 $ invested
14 	 17 	 (S[b]\NP)/NP 	 1 	 $ launch <XB>
15 	 14 	 N/N[num] 	 1 	 600,000 $
16 	 13 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to invested
17 	 16 	 (S[to]\NP)/(S[b]\NP) 	 2 	 launch to
19 	 17 	 (S[b]\NP)/NP 	 2 	 Inc. launch
19 	 18 	 N/N 	 1 	 Inc. Amira
24 	 22 	 (N/N)/(N/N) 	 2 	 Mass. Worcester
26 	 17 	 (S[b]\NP)/NP 	 2 	 concern launch
26 	 21 	 NP[nb]/N 	 1 	 concern a
26 	 24 	 N/N 	 1 	 concern Mass.
26 	 27 	 (NP\NP)/(S[dcl]\NP) 	 1 	 concern that
26 	 28 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 concern will <XB>
26 	 29 	 (S[b]\NP)/NP 	 1 	 concern produce <XB>
28 	 27 	 (NP\NP)/(S[dcl]\NP) 	 2 	 will that
29 	 28 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 produce will
30 	 29 	 (S[b]\NP)/NP 	 2 	 pharmaceuticals produce
<\s>
<s id="wsj_0975.14"> 16
2 	 0 	 N/N 	 1 	 Kaddurah-Daouk Scientists
2 	 1 	 N/N 	 1 	 Kaddurah-Daouk Rima
2 	 6 	 (S[dcl]\NP)/NP 	 1 	 Kaddurah-Daouk conducted
5 	 0 	 N/N 	 1 	 Schimmel Scientists
5 	 1 	 N/N 	 1 	 Schimmel Rima
5 	 4 	 N/N 	 1 	 Schimmel Paul
5 	 6 	 (S[dcl]\NP)/NP 	 1 	 Schimmel conducted
6 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 conducted at
9 	 6 	 (S[dcl]\NP)/NP 	 2 	 research conducted
9 	 7 	 NP[nb]/N 	 1 	 research the
9 	 8 	 N/N 	 1 	 research initial
13 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 Institute at
13 	 11 	 NP[nb]/N 	 1 	 Institute the
13 	 12 	 N/N 	 1 	 Institute Massachusetts
13 	 14 	 (NP\NP)/NP 	 1 	 Institute of
15 	 14 	 (NP\NP)/NP 	 2 	 Technology of
<\s>
<s id="wsj_0975.15"> 32
2 	 1 	 N/N 	 1 	 Kaddurah-Daouk Ms.
2 	 3 	 (S[dcl]\NP)/NP 	 1 	 Kaddurah-Daouk left
2 	 6 	 (S[b]\NP)/NP 	 1 	 Kaddurah-Daouk head <XB>
3 	 0 	 (S/S)/S[dcl] 	 2 	 left While
4 	 3 	 (S[dcl]\NP)/NP 	 2 	 MIT left
6 	 5 	 (S[to]\NP)/(S[b]\NP) 	 2 	 head to
7 	 6 	 (S[b]\NP)/NP 	 2 	 Amira head
10 	 9 	 N/N 	 1 	 Schimmel Prof.
10 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Schimmel will
10 	 12 	 (S[b]\NP)/(S[to]\NP) 	 1 	 Schimmel continue <XB>
10 	 14 	 S[b]\NP 	 1 	 Schimmel work <XB>
10 	 18 	 (S[b]\NP)/PP 	 1 	 Schimmel serve <XU>
10 	 24 	 (S[b]\NP)/NP 	 1 	 Schimmel own <XU>
11 	 0 	 (S/S)/S[dcl] 	 1 	 will While
12 	 11 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 continue will
13 	 12 	 (S[b]\NP)/(S[to]\NP) 	 2 	 to continue
14 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 work to
14 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 work at
16 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 MIT at
18 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 serve to
19 	 18 	 (S[b]\NP)/PP 	 2 	 on serve
20 	 21 	 (NP[nb]/N)\NP 	 2 	 Amira 's
22 	 19 	 PP/NP 	 1 	 board on
22 	 21 	 (NP[nb]/N)\NP 	 1 	 board 's
24 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 own to
28 	 24 	 (S[b]\NP)/NP 	 2 	 stake own
28 	 25 	 NP[nb]/N 	 1 	 stake a
28 	 26 	 N/N 	 1 	 stake small
28 	 27 	 N/N 	 1 	 stake equity
28 	 29 	 (NP\NP)/NP 	 1 	 stake in
31 	 29 	 (NP\NP)/NP 	 2 	 company in
31 	 30 	 NP[nb]/N 	 1 	 company the
<\s>
<s id="wsj_0975.16"> 18
2 	 0 	 NP[nb]/N 	 1 	 transaction The
2 	 1 	 N/N 	 1 	 transaction Amira
2 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 transaction is
2 	 4 	 (S[adj]\NP)/PP 	 1 	 transaction typical <XB>
4 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 typical is
5 	 4 	 (S[adj]\NP)/PP 	 2 	 of typical
7 	 5 	 PP/NP 	 1 	 way of
7 	 6 	 NP[nb]/N 	 1 	 way the
9 	 8 	 N/N 	 1 	 firms venture-capital
9 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 firms are
9 	 11 	 (S[ng]\NP)/NP 	 1 	 firms approaching <XB>
11 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 approaching are
13 	 11 	 (S[ng]\NP)/NP 	 2 	 task approaching
13 	 12 	 NP[nb]/N 	 1 	 task the
13 	 14 	 (NP\NP)/(S[ng]\NP) 	 1 	 task of
15 	 14 	 (NP\NP)/(S[ng]\NP) 	 2 	 commercializing of
17 	 15 	 (S[ng]\NP)/NP 	 2 	 research commercializing
17 	 16 	 N/N 	 1 	 research biotechnology
<\s>
<s id="wsj_0975.17"> 25
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 universities develop
2 	 0 	 (S/S)/S[dcl] 	 2 	 develop While
5 	 2 	 (S[dcl]\NP)/NP 	 2 	 research develop
5 	 3 	 NP[nb]/N 	 1 	 research the
5 	 4 	 N/N 	 1 	 research basic
8 	 7 	 N/N 	 1 	 capitalists venture
8 	 9 	 (S[dcl]\NP)/NP 	 1 	 capitalists are
9 	 0 	 (S/S)/S[dcl] 	 1 	 are While
9 	 19 	 (S[dcl]\S[dcl])/NP 	 1 	 are says
11 	 9 	 (S[dcl]\NP)/NP 	 2 	 ones are
11 	 10 	 NP[nb]/N 	 1 	 ones the
11 	 13 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 ones positioned <XB>
11 	 15 	 (S[b]\NP)/NP 	 1 	 ones finance <XB>
13 	 12 	 (S\NP)/(S\NP) 	 2 	 positioned best
14 	 13 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to positioned
15 	 14 	 (S[to]\NP)/(S[b]\NP) 	 2 	 finance to
17 	 15 	 (S[b]\NP)/NP 	 2 	 commercialization finance
17 	 16 	 NP[nb]/N 	 1 	 commercialization its
22 	 19 	 (S[dcl]\S[dcl])/NP 	 2 	 Doubleday says
22 	 20 	 N/N 	 1 	 Doubleday Gloria
22 	 21 	 N/N 	 1 	 Doubleday W.
22 	 23 	 (NP\NP)/NP 	 1 	 Doubleday of
24 	 23 	 (NP\NP)/NP 	 2 	 Commonwealth of
<\s>
<s id="wsj_0975.18"> 14
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 This is
4 	 1 	 (S[dcl]\NP)/NP 	 2 	 way is
4 	 2 	 NP[nb]/N 	 1 	 way the
4 	 3 	 N/N 	 1 	 way best
6 	 5 	 (S[to]\NP)/(S[b]\NP) 	 2 	 transfer to
7 	 6 	 ((S[b]\NP)/PP)/NP 	 3 	 technology transfer
9 	 6 	 ((S[b]\NP)/PP)/NP 	 2 	 off transfer
9 	 8 	 PP/PP 	 1 	 off straight
11 	 9 	 PP/NP 	 1 	 campuses off
11 	 10 	 NP[nb]/N 	 1 	 campuses the
11 	 12 	 (NP\NP)/NP 	 1 	 campuses of
13 	 12 	 (NP\NP)/NP 	 2 	 universities of
<\s>
<s id="wsj_0975.19"> 23
3 	 1 	 NP[nb]/N 	 1 	 guidelines the
3 	 2 	 N/N 	 1 	 guidelines new
3 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines could
3 	 5 	 ((S[b]\NP)/PP)/NP 	 1 	 guidelines prevent <XB>
4 	 0 	 S/S 	 1 	 could But
4 	 21 	 (S[dcl]\S[dcl])\NP 	 1 	 could point
5 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 prevent could
6 	 5 	 ((S[b]\NP)/PP)/NP 	 3 	 scientists prevent
6 	 7 	 (NP\NP)/NP 	 1 	 scientists like
9 	 7 	 (NP\NP)/NP 	 2 	 Schimmel like
9 	 8 	 N/N 	 1 	 Schimmel Prof.
10 	 5 	 ((S[b]\NP)/PP)/NP 	 2 	 from prevent
11 	 10 	 PP/(S[ng]\NP) 	 1 	 being from
12 	 11 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 involved being
13 	 12 	 (S[pss]\NP)/PP 	 2 	 with involved
14 	 13 	 PP/NP 	 1 	 start-ups with
14 	 16 	 (NP\NP)/NP 	 1 	 start-ups as
16 	 15 	 (NP\NP)/(NP\NP) 	 2 	 as such
17 	 16 	 (NP\NP)/NP 	 2 	 Amira as
20 	 19 	 N/N 	 1 	 capitalists venture
20 	 21 	 (S[dcl]\S[dcl])\NP 	 2 	 capitalists point
21 	 22 	 S\S 	 1 	 point out
<\s>
<s id="wsj_0975.20"> 20
2 	 3 	 S[dcl]\NP 	 1 	 that happens
3 	 1 	 (S/S)/S[dcl] 	 2 	 happens if
7 	 5 	 NP[nb]/N 	 1 	 process the
7 	 6 	 N/N 	 1 	 process entire
7 	 8 	 (NP\NP)/(S[ng]\NP) 	 1 	 process of
7 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 process could
7 	 16 	 S[pss]\NP 	 1 	 process harmed <XB>
9 	 8 	 (NP\NP)/(S[ng]\NP) 	 2 	 transferring of
9 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 transferring to
10 	 9 	 (S[ng]\NP)/NP 	 2 	 technology transferring
13 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 marketplace to
13 	 12 	 NP[nb]/N 	 1 	 marketplace the
14 	 0 	 S/S 	 1 	 could And
14 	 1 	 (S/S)/S[dcl] 	 1 	 could if
14 	 19 	 (S[dcl]\S[dcl])\NP 	 1 	 could say
15 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be could
16 	 15 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 harmed be
18 	 19 	 (S[dcl]\S[dcl])\NP 	 2 	 they say
<\s>
<s id="wsj_0975.21"> 7
1 	 0 	 NP[nb]/N 	 1 	 stakes The
1 	 2 	 (NP\NP)/NP 	 1 	 stakes in
1 	 5 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 stakes are
1 	 6 	 S[adj]\NP 	 1 	 stakes large <XB>
4 	 2 	 (NP\NP)/NP 	 2 	 controversy in
4 	 3 	 NP[nb]/N 	 1 	 controversy the
6 	 5 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 large are
<\s>
<s id="wsj_0975.22"> 32
1 	 0 	 (S/S)/(S/S) 	 2 	 year Last
4 	 3 	 N/N 	 1 	 capitalists venture
4 	 5 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 capitalists spent
5 	 1 	 S/S 	 1 	 spent year
5 	 21 	 ((S\NP)\(S\NP))/PP 	 2 	 spent according
8 	 5 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 $ spent
8 	 6 	 NP[nb]/N 	 1 	 $ an
8 	 7 	 N/N 	 1 	 $ estimated
8 	 12 	 (S[b]\NP)/NP 	 1 	 $ finance <XB>
10 	 8 	 N/N[num] 	 1 	 million $
10 	 9 	 N/N 	 1 	 million 600
11 	 5 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to spent
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 finance to
12 	 15 	 ((S\NP)\(S\NP))/NP 	 2 	 finance in
14 	 12 	 (S[b]\NP)/NP 	 2 	 companies finance
14 	 13 	 N/N 	 1 	 companies start-up
19 	 15 	 ((S\NP)\(S\NP))/NP 	 3 	 businesses in
19 	 16 	 N/N 	 1 	 businesses medical <XU>
19 	 18 	 N/N 	 1 	 businesses biotechnology
22 	 21 	 ((S\NP)\(S\NP))/PP 	 3 	 to according
27 	 22 	 PP/NP 	 1 	 Association to
27 	 23 	 NP[nb]/N 	 1 	 Association the
27 	 24 	 N/N 	 1 	 Association National
27 	 25 	 N/N 	 1 	 Association Venture
27 	 26 	 N/N 	 1 	 Association Capital
31 	 22 	 PP/NP 	 1 	 group to
31 	 29 	 NP[nb]/N 	 1 	 group a
31 	 30 	 N/N 	 1 	 group trade
<\s>
<s id="wsj_0975.23"> 25
0 	 1 	 (NP\NP)/NP 	 1 	 Many of
0 	 4 	 (S[dcl]\NP)/NP 	 1 	 Many involved
3 	 1 	 (NP\NP)/NP 	 2 	 deals of
3 	 2 	 NP[nb]/N 	 1 	 deals the
5 	 4 	 (S[dcl]\NP)/NP 	 2 	 transactions involved
5 	 7 	 ((NP\NP)/S[pt])\((NP\NP)/NP) 	 1 	 transactions which
6 	 7 	 ((NP\NP)/S[pt])\((NP\NP)/NP) 	 3 	 in which
9 	 8 	 N/N 	 1 	 institutions scientific
9 	 12 	 (S[pt]\NP)/(S[to]\NP) 	 1 	 institutions agreed
9 	 14 	 (S[b]\NP)/NP 	 1 	 institutions commercialize <XB>
11 	 8 	 N/N 	 1 	 researchers scientific
11 	 12 	 (S[pt]\NP)/(S[to]\NP) 	 1 	 researchers agreed
11 	 14 	 (S[b]\NP)/NP 	 1 	 researchers commercialize <XB>
12 	 7 	 ((NP\NP)/S[pt])\((NP\NP)/NP) 	 2 	 agreed which
12 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 agreed in
13 	 12 	 (S[pt]\NP)/(S[to]\NP) 	 2 	 to agreed
14 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 commercialize to
16 	 14 	 (S[b]\NP)/NP 	 2 	 work commercialize
16 	 15 	 NP[nb]/N 	 1 	 work their
18 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 return in
18 	 19 	 (NP\NP)/NP 	 1 	 return for
22 	 19 	 (NP\NP)/NP 	 2 	 stake for
22 	 20 	 NP[nb]/N 	 1 	 stake an
22 	 21 	 N/N 	 1 	 stake equity
24 	 19 	 (NP\NP)/NP 	 2 	 royalties for
<\s>
<s id="wsj_0975.24"> 24
1 	 0 	 (S/S)/NP 	 2 	 many In
1 	 2 	 (NP\NP)/NP 	 1 	 many of
4 	 2 	 (NP\NP)/NP 	 2 	 deals of
4 	 3 	 NP[nb]/N 	 1 	 deals these
7 	 6 	 N/N 	 1 	 capitalists venture
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 capitalists had
8 	 0 	 (S/S)/NP 	 1 	 had In
8 	 13 	 (S[dcl]\S[dcl])/NP 	 1 	 had says
11 	 8 	 (S[dcl]\NP)/NP 	 2 	 track had
11 	 9 	 NP[nb]/N 	 1 	 track the
11 	 10 	 N/N 	 1 	 track inside
15 	 13 	 (S[dcl]\S[dcl])/NP 	 2 	 Bock says
15 	 14 	 N/N 	 1 	 Bock Lawrence
15 	 16 	 (NP\NP)/NP 	 1 	 Bock of
18 	 16 	 (NP\NP)/NP 	 2 	 Ventures of
18 	 17 	 N/N 	 1 	 Ventures Avalon
18 	 21 	 NP\NP 	 1 	 Ventures Jolla
18 	 23 	 NP\NP 	 1 	 Ventures Calif <XU>
21 	 20 	 (NP\NP)/(NP\NP) 	 2 	 Jolla La
<\s>
<s id="wsj_0975.25"> 19
0 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Investors were
0 	 2 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 Investors willing <XB>
1 	 18 	 (S[dcl]\S[dcl])\NP 	 1 	 were adds
2 	 1 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 willing were
3 	 2 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to willing
4 	 3 	 (S[to]\NP)/(S[b]\NP) 	 2 	 gamble to
4 	 8 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 gamble because
5 	 4 	 (S[b]\NP)/PP 	 2 	 on gamble
7 	 5 	 PP/NP 	 1 	 technologies on
7 	 6 	 N/N 	 1 	 technologies new
9 	 10 	 (S[dcl]\NP)/NP 	 1 	 we had
10 	 8 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 had because
12 	 10 	 (S[dcl]\NP)/NP 	 2 	 rights had
12 	 11 	 N/N 	 1 	 rights exclusive
12 	 13 	 (NP\NP)/NP 	 1 	 rights to
15 	 13 	 (NP\NP)/NP 	 2 	 technologies to
15 	 14 	 NP[nb]/N 	 1 	 technologies those
17 	 18 	 (S[dcl]\S[dcl])\NP 	 2 	 he adds
<\s>
<s id="wsj_0975.26"> 24
4 	 1 	 (S/S)/NP 	 2 	 guidelines under
4 	 2 	 NP[nb]/N 	 1 	 guidelines the
4 	 3 	 N/N 	 1 	 guidelines proposed
8 	 7 	 (N/N)/(N/N) 	 2 	 funded federally
9 	 6 	 NP[nb]/N 	 1 	 research all
9 	 8 	 N/N 	 1 	 research funded
9 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 research will
9 	 14 	 S[pss]\NP 	 1 	 research reported <XB>
10 	 0 	 S/S 	 1 	 will But
10 	 1 	 (S/S)/NP 	 1 	 will under
11 	 10 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have will
12 	 11 	 (S[b]\NP)/(S[to]\NP) 	 2 	 to have
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
14 	 13 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 reported be
14 	 15 	 (S\NP)\(S\NP) 	 2 	 reported publicly
14 	 16 	 ((S\NP)\(S\NP))/S[em] 	 2 	 reported so
17 	 16 	 ((S\NP)\(S\NP))/S[em] 	 3 	 that so
18 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 anyone can
18 	 20 	 (S[b]\NP)/PP 	 1 	 anyone capitalize <XB>
19 	 17 	 S[em]/S[dcl] 	 1 	 can that
20 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 capitalize can
21 	 20 	 (S[b]\NP)/PP 	 2 	 on capitalize
23 	 21 	 PP/NP 	 1 	 work on
23 	 22 	 NP[nb]/N 	 1 	 work the
<\s>
<s id="wsj_0975.27"> 21
2 	 0 	 (S/S)/NP 	 2 	 exclusivity Without
2 	 1 	 NP[nb]/N 	 1 	 exclusivity the
6 	 4 	 N/N 	 1 	 capitalists most
6 	 5 	 N/N 	 1 	 capitalists venture
6 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 capitalists wo
6 	 9 	 (S[b]\NP)/NP 	 1 	 capitalists have <XB>
7 	 0 	 (S/S)/NP 	 1 	 wo Without
7 	 8 	 (S\NP)\(S\NP) 	 2 	 wo n't
7 	 20 	 (S[dcl]\S[dcl])\NP 	 1 	 wo says
9 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have wo
11 	 9 	 (S[b]\NP)/NP 	 2 	 incentive have
11 	 10 	 NP[nb]/N 	 1 	 incentive the
11 	 13 	 (S[b]\NP)/PP 	 1 	 incentive invest <XB>
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 invest to
14 	 13 	 (S[b]\NP)/PP 	 2 	 in invest
16 	 14 	 PP/NP 	 1 	 deals in
16 	 15 	 NP/NP 	 1 	 deals such
19 	 18 	 N/N 	 1 	 Bock Mr.
19 	 20 	 (S[dcl]\S[dcl])\NP 	 2 	 Bock says
<\s>
<s id="wsj_0975.28"> 36
1 	 0 	 (S/S)/(S/S) 	 2 	 year Last
4 	 3 	 (S/S)/NP 	 2 	 example for
6 	 9 	 (S[dcl]\NP)/NP 	 1 	 Avalon invested
6 	 25 	 (S[b]\NP)/NP 	 1 	 Avalon license <XB>
6 	 27 	 (S[b]\NP)/NP 	 1 	 Avalon develop <XU>
8 	 9 	 (S[dcl]\NP)/NP 	 1 	 others invested
8 	 25 	 (S[b]\NP)/NP 	 1 	 others license <XB>
8 	 27 	 (S[b]\NP)/NP 	 1 	 others develop <XU>
9 	 1 	 S/S 	 1 	 invested year
9 	 3 	 (S/S)/NP 	 1 	 invested for
9 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 invested in
10 	 9 	 (S[dcl]\NP)/NP 	 2 	 $ invested
12 	 10 	 N/N[num] 	 1 	 million $
12 	 11 	 N/N 	 1 	 million 14
16 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 Inc. in
16 	 14 	 N/N 	 1 	 Inc. Athena
16 	 15 	 N/N 	 1 	 Inc. Neurosciences
16 	 20 	 NP\NP 	 1 	 Inc. Francisco
16 	 22 	 NP\NP 	 1 	 Inc. Calif. <XU>
20 	 18 	 (NP\NP)/(NP\NP) 	 2 	 Francisco South
20 	 19 	 (NP\NP)/(NP\NP) 	 2 	 Francisco San
25 	 24 	 (S[to]\NP)/(S[b]\NP) 	 2 	 license to
27 	 24 	 (S[to]\NP)/(S[b]\NP) 	 2 	 develop to
28 	 25 	 (S[b]\NP)/NP 	 2 	 technology license <XU>
28 	 27 	 (S[b]\NP)/NP 	 2 	 technology develop
28 	 29 	 (NP\NP)/NP 	 1 	 technology for
30 	 29 	 (NP\NP)/NP 	 2 	 delivery for
30 	 31 	 (NP\NP)/NP 	 1 	 delivery of
30 	 33 	 (NP\NP)/NP 	 1 	 delivery to
32 	 31 	 (NP\NP)/NP 	 2 	 drugs of
35 	 33 	 (NP\NP)/NP 	 2 	 brain to
35 	 34 	 NP[nb]/N 	 1 	 brain the
<\s>
<s id="wsj_0975.29"> 40
2 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Athena was
2 	 4 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 Athena able <XB>
3 	 1 	 (S/S)/S[dcl] 	 2 	 was before
4 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 able was
5 	 4 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to able
6 	 5 	 (S[to]\NP)/(S[b]\NP) 	 2 	 get to
9 	 6 	 (S[b]\NP)/NP 	 2 	 license get
9 	 7 	 NP[nb]/N 	 1 	 license an
9 	 8 	 N/N 	 1 	 license exclusive
9 	 10 	 (NP\NP)/NP 	 1 	 license to
12 	 10 	 (NP\NP)/NP 	 2 	 technology to
12 	 11 	 NP[nb]/N 	 1 	 technology the
16 	 14 	 NP[nb]/N 	 1 	 Register the
16 	 15 	 N/N 	 1 	 Register Federal
16 	 17 	 (S[dcl]\NP)/NP 	 1 	 Register published
16 	 23 	 ((S[ng]\NP)/NP)/NP 	 1 	 Register giving <XB>
17 	 0 	 S/S 	 1 	 published But
17 	 1 	 (S/S)/S[dcl] 	 1 	 published before
17 	 39 	 (S[dcl]\S[dcl])\NP 	 1 	 published says
18 	 17 	 (S[dcl]\NP)/NP 	 2 	 most published
18 	 19 	 (NP\NP)/NP 	 1 	 most of
21 	 19 	 (NP\NP)/NP 	 2 	 details of
21 	 20 	 NP[nb]/N 	 1 	 details the
24 	 23 	 ((S[ng]\NP)/NP)/NP 	 3 	 all giving
24 	 25 	 (NP\NP)/NP 	 1 	 all of
27 	 26 	 NP[nb]/N 	 1 	 company the
27 	 28 	 (NP[nb]/N)\NP 	 2 	 company 's
30 	 25 	 (NP\NP)/NP 	 2 	 competitors of
30 	 28 	 (NP[nb]/N)\NP 	 1 	 competitors 's
30 	 29 	 N/N 	 1 	 competitors potential
32 	 23 	 ((S[ng]\NP)/NP)/NP 	 2 	 chance giving
32 	 31 	 NP[nb]/N 	 1 	 chance a
32 	 34 	 (S[b]\NP)/NP 	 1 	 chance exploit <XB>
34 	 33 	 (S[to]\NP)/(S[b]\NP) 	 2 	 exploit to
35 	 34 	 (S[b]\NP)/NP 	 2 	 it exploit
38 	 37 	 N/N 	 1 	 Bock Mr.
38 	 39 	 (S[dcl]\S[dcl])\NP 	 2 	 Bock says
<\s>
<s id="wsj_0975.30"> 13
0 	 2 	 (S[dcl]\NP)/NP 	 1 	 Athena acquired
0 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Athena is <XU>
0 	 11 	 (S[ng]\NP)/NP 	 1 	 Athena developing <XU>
2 	 1 	 (S\NP)/(S\NP) 	 2 	 acquired eventually
4 	 2 	 (S[dcl]\NP)/NP 	 2 	 rights acquired
4 	 3 	 N/N 	 1 	 rights exclusive
4 	 5 	 (NP\NP)/NP 	 1 	 rights to
7 	 5 	 (NP\NP)/NP 	 2 	 technology to
7 	 6 	 NP[nb]/N 	 1 	 technology the
10 	 9 	 (S\NP)/(S\NP) 	 2 	 is currently
11 	 10 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 developing is
12 	 11 	 (S[ng]\NP)/NP 	 2 	 it developing
<\s>
<s id="wsj_0975.31"> 11
2 	 0 	 S/S 	 1 	 says But
4 	 2 	 (S[dcl]/S[dcl])/NP 	 2 	 Bock says
4 	 3 	 N/N 	 1 	 Bock Mr.
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 It was
7 	 2 	 (S[dcl]/S[dcl])/NP 	 1 	 was says
10 	 7 	 (S[dcl]\NP)/NP 	 2 	 call was
10 	 8 	 NP[nb]/N 	 1 	 call a
10 	 9 	 N/N 	 1 	 call close
<\s>
<s id="wsj_0975.32"> 19
2 	 0 	 NP[nb]/N 	 1 	 guidelines The
2 	 1 	 N/N 	 1 	 guidelines proposed
2 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines could
2 	 5 	 (S[b]\NP)/NP 	 1 	 guidelines delay <XB>
2 	 9 	 ((S[b]\NP)/(S[to]\NP))/NP 	 1 	 guidelines force <XU>
3 	 4 	 (S\NP)\(S\NP) 	 2 	 could also
3 	 18 	 (S[dcl]\S[dcl])\NP 	 1 	 could say
5 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 delay could
6 	 5 	 (S[b]\NP)/NP 	 2 	 commercialization delay
9 	 3 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 force could
11 	 9 	 ((S[b]\NP)/(S[to]\NP))/NP 	 3 	 companies force
11 	 10 	 N/N 	 1 	 companies small
11 	 13 	 (S[b]\NP)/NP 	 1 	 companies waste <XB>
12 	 9 	 ((S[b]\NP)/(S[to]\NP))/NP 	 2 	 to force
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 waste to
15 	 13 	 (S[b]\NP)/NP 	 2 	 capital waste
15 	 14 	 N/N 	 1 	 capital scarce
17 	 18 	 (S[dcl]\S[dcl])\NP 	 2 	 entrepreneurs say
<\s>
<s id="wsj_0975.33"> 45
1 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 start-ups ca
1 	 4 	 (S[b]\NP)/NP 	 1 	 start-ups have <XB>
2 	 0 	 (S/S)/S[dcl] 	 2 	 ca If
2 	 3 	 (S\NP)\(S\NP) 	 2 	 ca n't
4 	 2 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have ca
6 	 4 	 (S[b]\NP)/NP 	 2 	 access have
6 	 5 	 N/N 	 1 	 access early
6 	 7 	 (NP\NP)/NP 	 1 	 access to
8 	 7 	 (NP\NP)/NP 	 2 	 research to
8 	 9 	 (S[ng]\NP)/(S[pss]\NP) 	 1 	 research being <XB>
8 	 10 	 S[pss]\NP 	 1 	 research conducted <XB>
10 	 9 	 (S[ng]\NP)/(S[pss]\NP) 	 2 	 conducted being
10 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 conducted at
12 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 institutions at
14 	 15 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 we have
14 	 17 	 (S[b]\NP)/NP 	 1 	 we replicate <XB>
14 	 21 	 (S[b]\NP)/PP 	 1 	 we do <XU>
15 	 0 	 (S/S)/S[dcl] 	 1 	 have If
15 	 26 	 (S[dcl]\S[dcl])/NP 	 1 	 have says
16 	 15 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to have
17 	 16 	 (S[to]\NP)/(S[b]\NP) 	 2 	 replicate to
17 	 19 	 (S\NP)\(S\NP) 	 2 	 replicate ourselves
18 	 17 	 (S[b]\NP)/NP 	 2 	 it replicate
21 	 16 	 (S[to]\NP)/(S[b]\NP) 	 2 	 do to
22 	 21 	 (S[b]\NP)/PP 	 2 	 without do
24 	 22 	 PP/NP 	 1 	 research without
24 	 23 	 NP[nb]/N 	 1 	 research the
28 	 26 	 (S[dcl]\S[dcl])/NP 	 2 	 Emyanitoff says
28 	 27 	 N/N 	 1 	 Emyanitoff Ruth
30 	 26 	 (S[dcl]\S[dcl])/NP 	 2 	 manager says
30 	 31 	 (NP\NP)/NP 	 1 	 manager of
30 	 34 	 (NP\NP)/NP 	 1 	 manager at
33 	 31 	 (NP\NP)/NP 	 2 	 development of
33 	 32 	 N/N 	 1 	 development business
37 	 34 	 (NP\NP)/NP 	 2 	 Inc. at
37 	 35 	 N/N 	 1 	 Inc. Applied
37 	 36 	 N/N 	 1 	 Inc. bioTechnology
42 	 40 	 (N/N)/(N/N) 	 2 	 Mass. Cambridge
44 	 34 	 (NP\NP)/NP 	 2 	 concern at
44 	 39 	 NP[nb]/N 	 1 	 concern a
44 	 42 	 N/N 	 1 	 concern Mass.
<\s>
<s id="wsj_0975.34"> 14
0 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Duplicating is
0 	 4 	 S[adj]\NP 	 1 	 Duplicating costly <XB>
0 	 6 	 S[adj]\NP 	 1 	 Duplicating time-consuming <XU>
1 	 0 	 (S[ng]\NP)/NP 	 2 	 research Duplicating
2 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 is for
2 	 13 	 (S[dcl]\S[dcl])\NP 	 1 	 is says
4 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 costly is
4 	 3 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 costly both
6 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 time-consuming is
6 	 3 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 time-consuming both
9 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 start-up for
9 	 8 	 NP[nb]/N 	 1 	 start-up a
12 	 11 	 N/N 	 1 	 Emyanitoff Ms.
12 	 13 	 (S[dcl]\S[dcl])\NP 	 2 	 Emyanitoff says
<\s>
<s id="wsj_0975.35"> 24
2 	 0 	 (S/S)/NP 	 2 	 part For
2 	 1 	 NP[nb]/N 	 1 	 part its
4 	 5 	 (S[dcl]\NP)/S[em] 	 1 	 NIH insists
5 	 0 	 (S/S)/NP 	 1 	 insists For
6 	 5 	 (S[dcl]\NP)/S[em] 	 2 	 that insists
8 	 7 	 NP[nb]/N 	 1 	 guidelines its
8 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines should
8 	 11 	 (S[b]\NP)/NP 	 1 	 guidelines stifle <XB>
9 	 6 	 S[em]/S[dcl] 	 1 	 should that
9 	 10 	 (S\NP)\(S\NP) 	 2 	 should not
11 	 9 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 stifle should
13 	 11 	 (S[b]\NP)/NP 	 2 	 creativity stifle
13 	 12 	 N/N 	 1 	 creativity research
16 	 11 	 (S[b]\NP)/NP 	 2 	 transfer stifle
16 	 15 	 N/N 	 1 	 transfer technology
16 	 17 	 (NP\NP)/NP 	 1 	 transfer from
16 	 21 	 (NP\NP)/NP 	 1 	 transfer to
20 	 17 	 (NP\NP)/NP 	 2 	 laboratory from
20 	 18 	 NP[nb]/N 	 1 	 laboratory the
20 	 19 	 N/N 	 1 	 laboratory research
23 	 21 	 (NP\NP)/NP 	 2 	 use to
23 	 22 	 N/N 	 1 	 use commercial
<\s>
<s id="wsj_0975.36"> 40
0 	 2 	 (NP\NP)/NP 	 1 	 Universities as
0 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Universities should
0 	 8 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 Universities able <XB>
2 	 1 	 (NP\NP)/(NP\NP) 	 2 	 as such
3 	 2 	 (NP\NP)/NP 	 2 	 Harvard as
5 	 2 	 (NP\NP)/NP 	 2 	 MIT as
6 	 22 	 (S[dcl]\S[dcl])/NP 	 1 	 should says
7 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be should
8 	 7 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 able be
9 	 8 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to able
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 develop to
12 	 10 	 (S[b]\NP)/NP 	 2 	 way develop
12 	 11 	 NP[nb]/N 	 1 	 way a
14 	 13 	 (S[to]\NP)/(S[b]\NP) 	 2 	 act to
15 	 14 	 (S[b]\NP)/PP 	 2 	 as act
16 	 15 	 PP/NP 	 1 	 brokers as
16 	 17 	 (NP\NP)/NP 	 1 	 brokers for
20 	 17 	 (NP\NP)/NP 	 2 	 scientists for
20 	 18 	 NP[nb]/N 	 1 	 scientists the
20 	 19 	 N/N 	 1 	 scientists individual
24 	 22 	 (S[dcl]\S[dcl])/NP 	 2 	 Bick says
24 	 23 	 N/N 	 1 	 Bick Katherine
24 	 26 	 (NP\NP)/(S[dcl]\NP) 	 1 	 Bick who
24 	 27 	 (S[dcl]\NP)/NP 	 1 	 Bick oversees <XB>
27 	 26 	 (NP\NP)/(S[dcl]\NP) 	 2 	 oversees who
27 	 33 	 ((S\NP)\(S\NP))/NP 	 2 	 oversees as
32 	 27 	 (S[dcl]\NP)/NP 	 2 	 program oversees
32 	 28 	 NP[nb]/N 	 1 	 program the
32 	 29 	 N/N 	 1 	 program huge
32 	 30 	 N/N 	 1 	 program NIH
32 	 31 	 N/N 	 1 	 program grants
36 	 33 	 ((S\NP)\(S\NP))/NP 	 3 	 director as
36 	 34 	 NP[nb]/N 	 1 	 director its
36 	 35 	 N/N 	 1 	 director deputy
36 	 37 	 (NP\NP)/NP 	 1 	 director for
39 	 37 	 (NP\NP)/NP 	 2 	 research for
39 	 38 	 N/N 	 1 	 research extramural
<\s>
<s id="wsj_0975.37"> 23
2 	 0 	 N/N 	 1 	 members NIH
2 	 1 	 N/N 	 1 	 members staff
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 members believe
5 	 4 	 NP[nb]/N 	 1 	 guidelines the
5 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 guidelines are
5 	 7 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 guidelines essential <XB>
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 are believe
7 	 6 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 essential are
8 	 7 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to essential
9 	 8 	 (S[to]\NP)/(S[b]\NP) 	 2 	 prevent to
11 	 9 	 (S[b]\NP)/NP 	 2 	 escalation prevent
11 	 10 	 NP[nb]/N 	 1 	 escalation the
11 	 12 	 (NP\NP)/NP 	 1 	 escalation of
13 	 12 	 (NP\NP)/NP 	 2 	 problems of
13 	 14 	 (NP\NP)/(S[dcl]\NP) 	 1 	 problems that
13 	 15 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 problems have <XB>
13 	 17 	 (S[pt]\NP)/(S[to]\NP) 	 1 	 problems begun <XB>
13 	 19 	 S[b]\NP 	 1 	 problems surface <XB>
15 	 14 	 (NP\NP)/(S[dcl]\NP) 	 2 	 have that
15 	 16 	 (S\NP)\(S\NP) 	 2 	 have already
17 	 15 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 begun have
18 	 17 	 (S[pt]\NP)/(S[to]\NP) 	 2 	 to begun
19 	 18 	 (S[to]\NP)/(S[b]\NP) 	 2 	 surface to
19 	 20 	 ((S\NP)\(S\NP))/NP 	 2 	 surface in
22 	 20 	 ((S\NP)\(S\NP))/NP 	 3 	 ventures in
22 	 21 	 N/N 	 1 	 ventures scientific
<\s>
<s id="wsj_0975.38"> 21
2 	 0 	 (S/S)/(S/S) 	 2 	 ago Not
2 	 1 	 (S/S)/(S/S) 	 2 	 ago long
4 	 5 	 (S[ng]\NP)/NP 	 1 	 scientists holding <XB>
4 	 12 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 scientists were
4 	 13 	 (S[pss]\NP)/PP 	 1 	 scientists accused <XB>
6 	 5 	 (S[ng]\NP)/NP 	 2 	 stock holding
6 	 7 	 (NP\NP)/NP 	 1 	 stock in
11 	 7 	 (NP\NP)/NP 	 2 	 Inc. in
11 	 8 	 N/N 	 1 	 Inc. Spectra
11 	 9 	 N/N 	 1 	 Inc. Pharmaceutical
11 	 10 	 N/N 	 1 	 Inc. Services
12 	 2 	 S/S 	 1 	 were ago
13 	 12 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 accused were
14 	 13 	 (S[pss]\NP)/PP 	 2 	 of accused
15 	 14 	 PP/(S[ng]\NP) 	 1 	 falsifying of
16 	 15 	 (S[ng]\NP)/NP 	 2 	 research falsifying
18 	 17 	 (S[to]\NP)/(S[b]\NP) 	 2 	 boost to
20 	 18 	 (S[b]\NP)/NP 	 2 	 stock boost
20 	 19 	 NP[nb]/N 	 1 	 stock the
<\s>
<s id="wsj_0975.39"> 14
1 	 0 	 N/N 	 1 	 officials Many
1 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 officials are
1 	 4 	 (S[adj]\NP)/PP 	 1 	 officials concerned <XB>
2 	 3 	 (S\NP)\(S\NP) 	 2 	 are also
4 	 2 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 concerned are
5 	 4 	 (S[adj]\NP)/PP 	 2 	 about concerned
6 	 5 	 PP/NP 	 1 	 companies about
6 	 7 	 (S[ng]\NP)/NP 	 1 	 companies getting <XB>
10 	 7 	 (S[ng]\NP)/NP 	 2 	 ride getting
10 	 8 	 NP[nb]/N 	 1 	 ride a
10 	 9 	 N/N 	 1 	 ride free
10 	 11 	 (NP\NP)/NP 	 1 	 ride on
13 	 11 	 (NP\NP)/NP 	 2 	 research on
13 	 12 	 N/N 	 1 	 research government-sponsored
<\s>
<s id="wsj_0975.40"> 18
2 	 0 	 NP[nb]/N 	 1 	 subcommitee A
2 	 1 	 N/N 	 1 	 subcommitee congressional
2 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 subcommitee has
2 	 5 	 (S[ng]\NP)/NP 	 1 	 subcommitee investigating <XB>
4 	 3 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been has
5 	 4 	 (S[pt]\NP)/(S[ng]\NP) 	 2 	 investigating been
8 	 5 	 (S[ng]\NP)/NP 	 2 	 abuse investigating
8 	 6 	 NP[nb]/N 	 1 	 abuse the
8 	 7 	 N/N 	 1 	 abuse potential
8 	 9 	 (NP\NP)/NP 	 1 	 abuse from
10 	 9 	 (NP\NP)/NP 	 2 	 researchers from
10 	 11 	 (S[ng]\NP)/NP 	 1 	 researchers holding <XB>
12 	 11 	 (S[ng]\NP)/NP 	 2 	 stock holding
12 	 13 	 (NP\NP)/NP 	 1 	 stock in
14 	 13 	 (NP\NP)/NP 	 2 	 companies in
14 	 15 	 (S[ng]\NP)/NP 	 1 	 companies exploiting <XB>
17 	 15 	 (S[ng]\NP)/NP 	 2 	 research exploiting
17 	 16 	 NP[nb]/N 	 1 	 research their
<\s>
<s id="wsj_0975.41"> 31
2 	 0 	 (S/S)/NP 	 2 	 provisions Among
2 	 1 	 N/N 	 1 	 provisions other
6 	 4 	 NP[nb]/N 	 1 	 guidelines the
6 	 5 	 N/N 	 1 	 guidelines NIH
6 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 guidelines would
6 	 8 	 ((S[b]\NP)/PP)/NP 	 1 	 guidelines prohibit <XB>
7 	 0 	 (S/S)/NP 	 1 	 would Among
8 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 prohibit would
9 	 8 	 ((S[b]\NP)/PP)/NP 	 3 	 researchers prohibit
11 	 8 	 ((S[b]\NP)/PP)/NP 	 3 	 members prohibit
11 	 12 	 (NP\NP)/NP 	 1 	 members of
15 	 12 	 (NP\NP)/NP 	 2 	 families of
15 	 13 	 NP[nb]/N 	 1 	 families their
15 	 14 	 N/N 	 1 	 families immediate
16 	 8 	 ((S[b]\NP)/PP)/NP 	 2 	 from prohibit
17 	 16 	 PP/(S[ng]\NP) 	 1 	 holding from
18 	 17 	 (S[ng]\NP)/NP 	 2 	 stock holding
18 	 19 	 (NP\NP)/NP 	 1 	 stock in
21 	 19 	 (NP\NP)/NP 	 2 	 company in
21 	 20 	 NP[nb]/N 	 1 	 company any
21 	 22 	 (NP\NP)/(S[dcl]\NP) 	 1 	 company that
21 	 23 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 company is <XB>
21 	 24 	 S[pss]\NP 	 1 	 company affected <XB>
23 	 22 	 (NP\NP)/(S[dcl]\NP) 	 2 	 is that
24 	 23 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 affected is
24 	 25 	 ((S\NP)\(S\NP))/NP 	 2 	 affected by
27 	 25 	 ((S\NP)\(S\NP))/NP 	 3 	 outcome by
27 	 26 	 NP[nb]/N 	 1 	 outcome the
27 	 28 	 (NP\NP)/NP 	 1 	 outcome of
30 	 28 	 (NP\NP)/NP 	 2 	 research of
30 	 29 	 NP[nb]/N 	 1 	 research their
<\s>
<s id="wsj_0975.42"> 26
1 	 0 	 N/N 	 1 	 Bick Ms.
1 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 Bick says
5 	 3 	 NP[nb]/N 	 1 	 administrator the
5 	 4 	 N/N 	 1 	 administrator NIH
5 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 administrator says
12 	 8 	 NP[nb]/N 	 1 	 community the
12 	 9 	 N/N 	 1 	 community business <XU>
12 	 11 	 N/N 	 1 	 community scientific
12 	 13 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 community is
12 	 14 	 (S[ng]\NP)/PP 	 1 	 community overreacting <XB>
13 	 7 	 (S[dcl]\NP)/S[dcl] 	 2 	 is says
14 	 13 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 overreacting is
15 	 14 	 (S[ng]\NP)/PP 	 2 	 to overreacting
16 	 15 	 PP/NP 	 1 	 what to <XB>
16 	 20 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 3 	 what meant <XU>
16 	 22 	 (S[b]\NP)/NP 	 1 	 what be <XU>
18 	 17 	 NP[nb]/N 	 1 	 agency the
18 	 20 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 1 	 agency meant
20 	 16 	 NP/(S[dcl]/NP) 	 1 	 meant what
20 	 19 	 (S\NP)/(S\NP) 	 2 	 meant merely
21 	 20 	 ((S[dcl]\NP)/(S[to]\NP))/NP 	 2 	 to meant
22 	 21 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
23 	 22 	 (S[b]\NP)/NP 	 2 	 ideas be
23 	 24 	 (NP\NP)/NP 	 1 	 ideas for
25 	 24 	 (NP\NP)/NP 	 2 	 discussion for
<\s>
<s id="wsj_0975.43"> 9
1 	 0 	 NP[nb]/N 	 1 	 predictions The
1 	 2 	 (NP\NP)/NP 	 1 	 predictions of
1 	 4 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 predictions are
1 	 5 	 S[adj]\NP 	 1 	 predictions premature <XB>
3 	 2 	 (NP\NP)/NP 	 2 	 doom of
4 	 8 	 (S[dcl]\S[dcl])\NP 	 1 	 are says
5 	 4 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 premature are
7 	 8 	 (S[dcl]\S[dcl])\NP 	 2 	 she says
<\s>
<s id="wsj_0975.44"> 19
2 	 3 	 (NP\NP)/NP 	 1 	 agencies like
2 	 6 	 (S[dcl]\NP)/NP 	 1 	 agencies circulate
5 	 3 	 (NP\NP)/NP 	 2 	 NIH like
5 	 4 	 NP[nb]/N 	 1 	 NIH the
6 	 1 	 (S/S)/S[dcl] 	 2 	 circulate when
7 	 6 	 (S[dcl]\NP)/NP 	 2 	 guidelines circulate
9 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 they 've
9 	 13 	 (S[pt]\NP)/NP 	 1 	 they formulated <XB>
10 	 0 	 S/S 	 1 	 've But
10 	 1 	 (S/S)/S[dcl] 	 1 	 've when
10 	 11 	 (S\NP)\(S\NP) 	 2 	 've often
10 	 12 	 (S\NP)\(S\NP) 	 2 	 've already
10 	 18 	 (S[dcl]\S[dcl])\NP 	 1 	 've say
13 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 formulated 've
14 	 13 	 (S[pt]\NP)/NP 	 2 	 policy formulated
17 	 16 	 N/N 	 1 	 scientists veteran
17 	 18 	 (S[dcl]\S[dcl])\NP 	 2 	 scientists say
<\s>
<s id="wsj_0975.45"> 7
2 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 institutions are
2 	 5 	 (S[ng]\NP)/NP 	 1 	 institutions taking <XB>
4 	 0 	 S/S 	 1 	 are Indeed
4 	 3 	 (S\NP)/(S\NP) 	 2 	 are already
5 	 4 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 taking are
6 	 5 	 (S[ng]\NP)/NP 	 2 	 note taking
<\s>
<s id="wsj_0975.46"> 22
1 	 0 	 (S/S)/NP 	 2 	 Sept. On
2 	 1 	 N/N[num] 	 1 	 14 Sept.
4 	 5 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Harvard began
4 	 6 	 (S[ng]\NP)/NP 	 1 	 Harvard circulating <XB>
5 	 0 	 (S/S)/NP 	 1 	 began On
6 	 5 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 circulating began
10 	 6 	 (S[ng]\NP)/NP 	 2 	 statement circulating
10 	 7 	 NP[nb]/N 	 1 	 statement a
10 	 8 	 N/N 	 1 	 statement conflict-of-interest
10 	 9 	 N/N 	 1 	 statement policy
10 	 11 	 (NP\NP)/(S[dcl]\NP) 	 1 	 statement that
10 	 16 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 statement would <XB>
10 	 17 	 (S[b]\NP)/NP 	 1 	 statement follow <XB>
14 	 13 	 ((S\NP)/(S\NP))/NP 	 3 	 effect in
16 	 11 	 (NP\NP)/(S[dcl]\NP) 	 2 	 would that
16 	 13 	 ((S\NP)/(S\NP))/NP 	 2 	 would in
17 	 16 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 follow would
17 	 21 	 (S\NP)\(S\NP) 	 2 	 follow faithfully
20 	 17 	 (S[b]\NP)/NP 	 2 	 guidelines follow
20 	 18 	 NP[nb]/N 	 1 	 guidelines the
20 	 19 	 N/N 	 1 	 guidelines NIH
<\s>
<s id="wsj_0975.47"> 25
1 	 0 	 NP[nb]/N 	 1 	 University The
1 	 2 	 (NP\NP)/NP 	 1 	 University of
1 	 4 	 (NP\NP)/NP 	 1 	 University at
1 	 7 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 University is
1 	 9 	 ((S[ng]\NP)/PP)/NP 	 1 	 University circulating <XB>
1 	 17 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 University will <XB>
1 	 18 	 (S[b]\NP)/NP 	 1 	 University restrict <XB>
3 	 2 	 (NP\NP)/NP 	 2 	 California of
6 	 4 	 (NP\NP)/NP 	 2 	 Francisco at
6 	 5 	 N/N 	 1 	 Francisco San
7 	 8 	 (S\NP)\(S\NP) 	 2 	 is also
9 	 7 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 circulating is
9 	 16 	 ((S\NP)\(S\NP))/(S[dcl]\NP) 	 2 	 circulating that
11 	 9 	 ((S[ng]\NP)/PP)/NP 	 3 	 memo circulating
11 	 10 	 NP[nb]/N 	 1 	 memo a
12 	 9 	 ((S[ng]\NP)/PP)/NP 	 2 	 among circulating
15 	 12 	 PP/NP 	 1 	 faculty among
15 	 13 	 NP[nb]/N 	 1 	 faculty its
15 	 14 	 N/N 	 1 	 faculty scientific
17 	 16 	 ((S\NP)\(S\NP))/(S[dcl]\NP) 	 3 	 will that
18 	 17 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 restrict will
19 	 18 	 (S[b]\NP)/NP 	 2 	 contact restrict
19 	 20 	 (NP\NP)/NP 	 1 	 contact with
22 	 20 	 (NP\NP)/NP 	 2 	 world with
22 	 21 	 NP[nb]/N 	 1 	 world the
22 	 23 	 (NP\NP)/NP 	 1 	 world of
24 	 23 	 (NP\NP)/NP 	 2 	 business of
<\s>
<s id="wsj_0975.48"> 18
3 	 0 	 (S/S)/NP 	 2 	 institutions In
3 	 1 	 N/N 	 1 	 institutions many
3 	 2 	 N/N 	 1 	 institutions other
5 	 6 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 scientists are
5 	 7 	 (S[ng]\NP)/NP 	 1 	 scientists shunning <XB>
6 	 0 	 (S/S)/NP 	 1 	 are In
7 	 6 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 shunning are
7 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 shunning until
8 	 7 	 (S[ng]\NP)/NP 	 2 	 contacts shunning
8 	 9 	 (NP\NP)/NP 	 1 	 contacts with
11 	 9 	 (NP\NP)/NP 	 2 	 investors with
11 	 10 	 N/N 	 1 	 investors venture
15 	 13 	 NP[nb]/N 	 1 	 policy the
15 	 14 	 N/N 	 1 	 policy NIH
15 	 16 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 policy is
15 	 17 	 S[pss]\NP 	 1 	 policy settled <XB>
16 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 is until
17 	 16 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 settled is
<\s>
<s id="wsj_0975.49"> 19
2 	 0 	 (S[dcl]/S[dcl])/NP 	 2 	 Daly Says
2 	 1 	 N/N 	 1 	 Daly Mr.
6 	 0 	 (S[dcl]/S[dcl])/NP 	 2 	 capitalist Says
6 	 4 	 NP[nb]/N 	 1 	 capitalist the
6 	 5 	 N/N 	 1 	 capitalist venture
8 	 9 	 (S[dcl]\NP[expl])/(S[b]\NP) 	 1 	 It does
9 	 0 	 (S[dcl]/S[dcl])/NP 	 1 	 does Says
9 	 10 	 (S\NP)\(S\NP) 	 2 	 does n't
11 	 9 	 (S[dcl]\NP[expl])/(S[b]\NP) 	 2 	 matter does
12 	 11 	 (S[b]\NP)/S[qem] 	 2 	 whether matter
13 	 14 	 ((S[dcl]\NP)/NP)/NP 	 1 	 they call
14 	 12 	 S[qem]/S[dcl] 	 1 	 call whether
15 	 14 	 ((S[dcl]\NP)/NP)/NP 	 3 	 it call
16 	 14 	 ((S[dcl]\NP)/NP)/NP 	 2 	 guidelines call
18 	 14 	 ((S[dcl]\NP)/NP)/NP 	 2 	 policy call
<\s>
<s id="wsj_0975.50"> 5
1 	 0 	 NP[nb]/N 	 1 	 damage The
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 damage is
1 	 4 	 S[pss]\NP 	 1 	 damage done <XB>
2 	 3 	 (S\NP)\(S\NP) 	 2 	 is already
4 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 done is
<\s>
